000 01464 a2200421 4500
005 20250517112722.0
264 0 _c20170726
008 201707s 0 0 eng d
022 _a1932-6203
024 7 _a10.1371/journal.pone.0161660
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDöring, Jan Henje
245 0 0 _aThirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
_h[electronic resource]
260 _bPloS one
_c2016
300 _ae0161660 p.
_bdigital
500 _aPublication Type: Historical Article; Journal Article
650 0 4 _aAnticonvulsants
_xhistory
650 0 4 _aCross-Sectional Studies
650 0 4 _aDatabases, Pharmaceutical
650 0 4 _aDrug Approval
650 0 4 _aDrug Discovery
_xhistory
650 0 4 _aEurope
650 0 4 _aHistory, 20th Century
650 0 4 _aHistory, 21st Century
650 0 4 _aHumans
650 0 4 _aLegislation, Drug
650 0 4 _aOrphan Drug Production
_xhistory
650 0 4 _aRare Diseases
_xdrug therapy
650 0 4 _aResearch Design
650 0 4 _aSeizures
_xdrug therapy
650 0 4 _aUnited States
650 0 4 _aUnited States Food and Drug Administration
700 1 _aLampert, Anette
700 1 _aHoffmann, Georg F
700 1 _aRies, Markus
773 0 _tPloS one
_gvol. 11
_gno. 8
_gp. e0161660
856 4 0 _uhttps://doi.org/10.1371/journal.pone.0161660
_zAvailable from publisher's website
999 _c26356879
_d26356879